Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 17, 2007

View Archived Issues

Motavizumab safe in children treated for a second respiratory syncytial virus season

Diindolylmethane a possible alternative to surgery for cervical dysplasia

Increased CSF levels of NGF and BDNF detected in patients with migraine or PFMS

Rights to civamide acquired by OPKO Health

NIAID expands Imvamune smallpox vaccine trials in persons with atopic dermatitis

Ariad and Icon codevelop deforolimus-eluding stents

Maas Biolab awarded NIH grant to develop intrathecal ciclosporin

Amarillo Biosciences issues update on clinical trials

Novel agents for musculoskeletal and connective tissue disorders disclosed in recent patents

Alpharma to license U.S. rights for topical NSAID pain drug

Covidien and BioSynthema sign agreement for nuclear medicine cancer therapy

Results for BDM-E phase I/II clinical trial

Positive phase IIa clinical study results for MN-221 in status asthmaticus

Hisamitsu reports results of phase III HFT-290 trial

Nile reports positive phase I results for CD-NP in heart failure

Masitinib mesylate safe and effective in indolent systemic mastocytosis

Preclinical safety study of GSAO, a potential anticancer compound

Pozen responds to FDA approvable letter for Trexima

The FDA extends regulatory review period for Tysabri for Crohn's disease

Hycamtin approved for treatment of relapsed small cell lung cancer

Partial hold on clinical development of Telcyta removed

FDA approves Ixempra for the treatment of advanced breast cancer

Recent AstraZeneca patent describes novel therapeutic agents for respiratory disorders

New agents for treating HIV infection reported in recent Trimeris patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...